Influence of Dicoumarol Derivatives on Plasma Fibrinolytic System

Summary

The influence of some coumarine derivatives (anticoagulant drugs: pelentan [tromexan], sintrom, marcoumar) on plasma fibrinolytic activity has been investigated. The cases studied included a number of patients with coronary thrombosis treated in long-term anticoagulant therapy and rabbits treated with a single dose of the drug.

The anticoagulants have no significant effect either on fibrinogen or plasminogen level. All of the above mentioned drugs cause a prolongation of the euglobulin fibrinolysis time and an increase of the antiplasmin level. These two changes may be correlated to the prolongation of the prothrombin time.

The authors suggest that the described phenomena may be useful for biological and clinical evaluation of anticoagulant drugs.

 

MissingLinkText

 

 

MissingLinkText

• References

• 1 Alexander B, Landwehr G. Evolution of prothrombin conversion accelerator in stored human plasma and prothrombin fractions. Amer. J. Physiol 1949; 159: 332
• 2 Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem. Biophys 1952; 40: 346
• 3 Bachmann F, Duckert F, Geiger H, Baer P, Koller F. Differentiation of factor VII complex. Studies on the Stuart-Prower factor. Thromb. Diath. haem 1957; 1: 169
• 4 Buluk K, Januszko T. Heparyna a fibrynoliza. Patol. pol 1957; 8: 107
• 5 Douglas A. S. A mode of action of coumarin drugs. Brit. med. Bull 1955; 11: 39
• 6 Elsner P. Fibrinolyse in Schwangerschaft und Geburt. Fortschritte der Geburtshilfe und Gynäkologie, Nr. S. Karger, Basel; New York: 1957: 6
• 7 Halse T. Fibrinolyse. Freiburg (1948), Cantor ed
• 8 Irish V. V, Jaques L. B. The effect of dicoumarol upon plasma fibrinogen. Amer. J. Physiol 1945; 143: 101
• 9 Koller F, Loeliger A, Duckert F. Experiments on a new clotting Factor (Factor VII). Acta haemat. (Basel) 1951; 6: 1
• 10 Koller F. Le Facteur X. Rev. Hémat 1952; 10: 362
• 11 Kopec M, Niewiarowski S. Czynnosc fibrynolityczna osocza osob zdrowych. Pol. Arch. Med. wewnet 1956; 26: 1322
• 12 Kowalski E, Latallo Z, Niewiarowski S. Untersuchungen über die Aktivierung von Plasminogen und Inaktivierung von Plasmin. Folia haemat. (Lpz.) 1957; 75: 225
• 13 Kowarzyk H, Buluk K. Postepy badan nad krzepnieciem krwi. Postepy Medy-cyny Doswiadczalnej i Higieny 1950; 2: 1
• 14 McElfresh A. E, Özge A. The effect of coumarin drugs upon Plasma Thromboplastin Component. J. Lab. clin. Med 1957; 49: 753
• 14a Niewiarowska M. L’influence de l’hypothermie par refroidissement sur la coagulation du sang et sur la fibrinolyse chez le chat. Rev. Hémat 1957; 12: 650
• 15 Niewiarowski S, Latallo Z. unpublished
• 16 Quick A. J. Hemorrhagic Diseases. Lea and Febiger; Philadelphia: 1957
• 17 Rechnic M, Siwinska M, Czerwinska B. Antyfibrynolizyna krwi a thrombinogeneza. Arch. Immunol. Ter. Dosw 1957; 5: 347
• 18 Sise H. S, Kumball D. M, Adams D. Plasma Thromboplastin Component Deficiency produced by prolonged administration of prothrombopenic anticoagulants. Proc. Soc. exp. Biol. (N. Y.) 1955; 89: 91
• 19 Smith W. B, Rosenfeld R, Shinovara G. Y. Human plasma fibrinogen levels in various pathological states. Fed. Proc 1951; 10: 371
• 20 Wessler S. Studies on intravascular coagulation, II. A comparison of the effect of dicoumarol and heparin on clot formation in isolated venous segments. J. clin. Invest 1953; 32: 652
• 21 Witte S. Profibrinolysin, Thrombin-Inhibitor und Antithrombin bei Thrombose und während einer antikoagulierender Therapie. Intern. Tagung über Thrombose und Embolie; Basel: 1954